Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PSEUDO-12 vs ADVIL CONGESTION RELIEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Decongestant; acts on alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction, reducing edema and nasal congestion.
ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction
FDA: Temporary relief of nasal congestion due to colds, allergies, or sinusitis,Off-label: Adjunct in otitis media, eustachian tube dysfunction
temporary relief of nasal congestion,sinus pressure,headache,fever,minor aches and pains associated with common cold or flu
60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.
1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.
Terminal elimination half-life: 4-6 hours (adults); 6-8 hours (children); prolonged in renal impairment (up to 20 hours in severe disease).
Ibuprofen: 2-4 hours (short half-life requires frequent dosing). Pseudoephedrine: 5-8 hours (longer in alkaline urine). Context: Half-life prolonged in renal impairment.
Hepatic metabolism via N-demethylation (CYP3A4) and glucuronidation; minor renal excretion as unchanged drug.
ibuprofen: primarily hepatic via CYP2C9; phenylephrine: primarily hepatic via monoamine oxidase (MAO) and sulfation
Renal: 70-90% as unchanged drug; biliary/fecal: <10%
Renal: ~90% as unchanged drug and metabolites (ibuprofen: <10% unchanged, pseudoephedrine: 43-96% unchanged). Biliary/fecal: minimal (<5%).
Binding: 30-40%; primarily to albumin.
Ibuprofen: >99% bound to albumin. Pseudoephedrine: 20-30% bound to albumin.
Vd: 2.6-3.5 L/kg; indicates extensive tissue distribution (e.g., lungs, liver, kidney).
Ibuprofen: 0.1-0.2 L/kg (low, reflects high protein binding). Pseudoephedrine: 2.6-3.5 L/kg (extensive tissue distribution).
Oral: 90-100% (immediate-release); 80-90% (extended-release).
Oral: Ibuprofen ~80-100% (high), Pseudoephedrine ~100% (high).
e GFR 30-50 m L/min: 30 mg every 6 hours as needed; maximum 120 mg/day. e GFR <30 m L/min: 30 mg every 12 hours as needed; maximum 60 mg/day.
Avoid use if Cr Cl <30 m L/min. For Cr Cl 30-59 m L/min, use lowest effective dose and shortest duration.
Child-Pugh A: no adjustment. Child-Pugh B: 30 mg every 6 hours as needed; maximum 120 mg/day. Child-Pugh C: use is not recommended.
Avoid use in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use with caution and at the lowest effective dose.
Children 6-12 years: 30 mg orally every 4-6 hours; maximum 120 mg/day. Children 12-17 years: same as adult dosing.
Not recommended in children under 12 years of age due to phenylephrine component. For children 12 years and older, same as adult dosing.
Initiate at 30 mg every 6 hours as needed; maximum 120 mg/day due to increased sensitivity and higher risk of adverse effects.
Start at the low end of dosing range; avoid use in patients 65 years and older if possible due to increased risk of adverse effects; if necessary, use lowest effective dose for shortest duration.
None.
ibuprofen carries a black box warning for increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal, and for serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines
Cardiovascular effects: hypertension, palpitations, arrhythmias; CNS stimulation: insomnia, anxiety, tremor; exacerbation of glaucoma, hyperthyroidism, diabetes; urinary retention in prostatic hypertrophy; rebound congestion with prolonged use.
cardiovascular risk,gastrointestinal risk,renal effects,avoid concomitant use of other NSAIDs,hypertension,hyperthyroidism,diabetes,heart disease,use with MAOIs may cause hypertensive crisis
Severe hypertension, coronary artery disease, concurrent MAO inhibitor therapy, narrow-angle glaucoma, urinary retention, hypersensitivity to sympathomimetics.
hypersensitivity to ibuprofen, phenylephrine, or any component,history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs,perioperative pain in setting of coronary artery bypass graft (CABG) surgery,severe hypertension,severe coronary artery disease,use of MAOIs or within 14 days of stopping MAOIs
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented products) if taking MAOIs concurrently. Limit caffeine-containing beverages as they may increase CNS stimulation.
Avoid alcohol consumption due to increased risk of GI bleeding and liver damage. No specific food interactions; take with food or milk to reduce stomach upset. Caffeine may exacerbate pseudoephedrine's stimulant effects; limit caffeine intake.
FDA Pregnancy Category C. First trimester: no evidence of structural teratogenicity in human studies but avoid due to potential vasoconstriction. Second/third trimester: risk of fetal tachycardia, decreased placental perfusion, and potential for maternal hypertension; prolonged use may cause fetal hypoxia.
First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and premature ductus arteriosus constriction. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Phenylephrine: Limited human data; animal studies show fetal abnormalities at high doses; avoid in first trimester due to potential vascular disruption.
Excreted into breast milk in low amounts (M/P ratio ~0.5). Considered safe at recommended doses; however, monitor infant for irritability or insomnia.
Ibuprofen: Excreted into breast milk in low amounts (M/P ratio ~0.07). Compatible with breastfeeding; minimal infant exposure. Phenylephrine: Not known if excreted in breast milk; M/P ratio unknown. Avoid due to potential for infant hypertension and irritability. Alternative decongestants preferred.
No specific dose adjustment required; however, use lowest effective dose for shortest duration due to physiologic changes (increased renal clearance may slightly reduce plasma levels).
Pharmacokinetic changes in pregnancy: Increased volume of distribution and clearance for ibuprofen may require higher doses, but avoid due to fetal risks. No standard dose adjustment recommended; use lowest effective dose for shortest duration. Phenylephrine: No specific dosing adjustments in pregnancy; avoid use due to limited safety data.
Pseudoephedrine is a sympathomimetic amine used as a decongestant. It is contraindicated in severe hypertension, coronary artery disease, and concurrent MAOI use. Monitor for CNS stimulation, insomnia, and elevated blood pressure. Extended-release formulations should not be crushed or chewed.
Advil Congestion Relief combines ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen can cause nephrotoxicity; pseudoephedrine can elevate blood pressure and heart rate. Avoid in patients with uncontrolled hypertension, severe CAD, or MAOI use within 14 days. Use with caution in elderly due to increased risk of GI bleeding and CNS effects. Not recommended for children under 12 years.
Do not use if you have high blood pressure or heart disease unless directed by a doctor.,Avoid taking within 4 hours of bedtime to prevent insomnia.,Do not crush or chew extended-release tablets.,Limit caffeine intake while taking this medication.,Stop use and consult a doctor if symptoms persist after 7 days.
Do not take more than directed; do not use with other products containing ibuprofen or other NSAIDs (e.g., naproxen, aspirin) due to increased risk of stomach bleeding.,Avoid alcohol while taking this medication to reduce the risk of stomach irritation and bleeding.,Pseudoephedrine may cause insomnia, nervousness, or dizziness; take the last dose at least 4-6 hours before bedtime.,Stop use and consult a doctor if symptoms persist after 5 days (fever >3 days), if new symptoms appear, or if you experience signs of stomach bleeding (black/bloody stools, vomit with blood/coffee-grounds).,Do not use if you have heart disease, high blood pressure, thyroid disease, diabetes, glaucoma, or difficulty urinating due to an enlarged prostate unless directed by a doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PSEUDO-12 vs ADVIL CONGESTION RELIEF, answered by our medical review team.
PSEUDO-12 is a Decongestant that works by Decongestant; acts on alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction, reducing edema and nasal congestion.. ADVIL CONGESTION RELIEF is a NSAID/Decongestant Combination that works by ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PSEUDO-12 and ADVIL CONGESTION RELIEF depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PSEUDO-12 is: 60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.. The standard adult dose of ADVIL CONGESTION RELIEF is: 1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PSEUDO-12 and ADVIL CONGESTION RELIEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PSEUDO-12 is classified as Category C. FDA Pregnancy Category C. First trimester: no evidence of structural teratogenicity in human studies but avoid due to potential vasoconstriction. Second/third trimester: risk of fe. ADVIL CONGESTION RELIEF is classified as Category C. First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.